Welcome to DukeHealth.org.
Skip over navigation
  • Home
  • Patient and Visitor Info
  • Physicians
  • Services
  • Clinical Trials
  • Event Calendar
  • Locations
  • Health Library
  • About Duke Medicine

Quick Links

  • Appointments
  • HealthView Patient Login
  • Quality and Safety
Home > Physicians > Havrilesky, Laura J.
Jumbo Large Regular Text:
Print
Physicians

Laura J. Havrilesky, MD, MHSc

Related Content

Locations

  • Duke Gynecology/Oncology

Services

  • Gynecologic Cancer
  • Gynecologic Oncology

Health Library

  • Best Doctors 2011-2012 Award Winners
  • Biological Diversity of Ovarian Cancer Lessens Value of Screening

Share

Laura J. Havrilesky, MD, MHSc

Department / Division
Obstetrics/Gynecology / Gynecology Oncology

Address
DUMC 3079
Durham, NC 27710

Appointment Telephone
919-684-3765

Office Telephone
919-684-3765

Fax Telephone
919-684-8719

Training
  • MD, Duke University School of Medicine, 1995

Residency
  • OB-GYN, Duke University Medical Center, 1995-1999

Fellowship
  • Gynecologic Oncology, Duke University Medical Center, 1999-2002

Other Training
  • MHSc, Duke University, 2008

Clinical Interests
Gynecologic malignancies, premalignant disease of the cervix and vagina, radical pelvic surgery, chemotherapy, immunotherapy and radiation therapy, reconstructive pelvic surgery, laser surgery, complicated gynecologic surgery, hereditary ovarian cancer

Research Interests
I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Industry Relationships and Collaborations (What's this?)

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

  • Smith & Nephew plc

Representative Publications
Havrilesky, LJ; Cragun, JM; Calingaert, B; Alvarez Secord, A; Valea, FA; Clarke-Pearson, DL; Berchuck, A; Soper, JT. The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecologic Oncology. 2007;104:401-405. (2007) Abstract

Havrilesky, LJ; Secord, AA; Bae-Jump, V; Ayeni, T; Calingaert, B; Clarke-Pearson, DL; Berchuck, A; Gehrig, PA. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecologic Oncology. 2007;105:677-682. (2007) Abstract

Havrilesky, LJ; Secord, AA; Kulasingam, S; Myers, E. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Gynecologic Oncology. 2007;107:211-218. (2007) Abstract

Cragun, JM; Havrilesky, LJ; Calingaert, B; Synan, I; Secord, AA; Soper, JT; Clarke-Pearson, DL; Berchuck, A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. Journal of Clinical Oncology. 2005;23:3668-3675. (2005) Abstract

Havrilesky, LJ; Cragun, JM; Calingaert, B; Synan, I; Secord, AA; Soper, JT; Clarke-Pearson, DL; Berchuck, A. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecologic Oncology. 2005;99:689-695. (2005) Abstract

Havrilesky, LJ; Kulasingam, SL; Matchar, DB; Myers, ER. FDG-PET for management of cervical and ovarian cancer. Gynecologic Oncology. 2005;97:183-191. (2005) Abstract

Havrilesky, LJ; Leath, CA; Huh, W; Calingaert, B; Bentley, RC; Soper, JT; Alvarez Secord, A. Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. Gynecologic Oncology. 2004;93:429-434. (2004) Abstract

Havrilesky, LJ; Alvarez, AA; Sayer, RA; Lancaster, JM; Soper, JT; Berchuck, A; Clarke-Pearson, DL; Rodriguez, GC; Carney, ME. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecologic Oncology. 2003;88:51-57. (2003) Abstract

Havrilesky, LJ; Peterson, BL; Dryden, DK; Soper, JT; Clarke-Pearson, DL; Berchuck, A. Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstetrics and Gynecology. 2003;102:243-251. (2003) Abstract

Contact Us | Careers | Privacy Policy | Make a Gift | Site Map | RSS Feeds | En EspaƱol | Mobile Site | Help
Duke Medicine | Duke School of Medicine | Duke Children's | Duke University
Toll-Free: 888-ASK-DUKE (888-275-3853)
Copyright © 2004-2013 Duke University Health System

About This Page

Updated: Dec. 14, 2010
Published: Dec. 12, 2006
URL: http://www.dukehealth.org/physicians/laura_j_havrilesky